Company news
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) news
Aclaris Therapeutics, Inc. news releases on 6ix. Latest, Jun 6, 2024: Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare…
Press releases — page 2
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 5, 2024
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 6, 2024
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
April 29, 2024
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
April 22, 2024
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
February 26, 2024
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
January 15, 2024
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
January 9, 2024
Aclaris Therapeutics Provides Corporate Update
December 18, 2023
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
December 4, 2023
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
November 12, 2023
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
November 5, 2023
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
October 2, 2023
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
September 19, 2023
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor
September 17, 2023
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
August 6, 2023
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)
June 12, 2023
Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences
June 1, 2023
Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update
May 7, 2023
Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023
May 1, 2023
Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
March 26, 2023
Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa
March 5, 2023
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
February 22, 2023
Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference
February 8, 2023
Aclaris Therapeutics Provides 2023 Outlook
January 5, 2023
Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China
November 28, 2022
Aclaris Therapeutics Announces Key Leadership Transitions
November 21, 2022
Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences
November 9, 2022
Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
November 7, 2022
Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations
September 26, 2022
Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 29, 2022
Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata
August 24, 2022
Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
August 2, 2022
Aclaris Therapeutics Expands Leadership Team
July 31, 2022
Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference
May 31, 2022
Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 15, 2022
Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 9, 2022
Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium
May 2, 2022
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
February 23, 2022
Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference
February 1, 2022
Aclaris Therapeutics Provides R&D Update
January 10, 2022
Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference
December 26, 2021
Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine
December 2, 2021
Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021
November 17, 2021
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
November 2, 2021
Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
November 1, 2021
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action
August 26, 2021
Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
August 4, 2021
Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021
July 7, 2021
Aclaris Announces Pricing of Public Offering of Common Stock
June 8, 2021
Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
June 7, 2021